Noxopharm Limited Stock price

Equities

NOX

AU000000NOX9

Pharmaceuticals

Market Closed - Australian S.E. 01:10:09 2024-03-28 am EDT 5-day change 1st Jan Change
0.067 AUD +3.08% Intraday chart for Noxopharm Limited -9.46% -5.63%
Sales 2022 5.43M 3.52M Sales 2023 6.01M 3.9M Capitalization 12.57M 8.15M
Net income 2022 -18M -11.68M Net income 2023 -15M -9.73M EV / Sales 2022 7.95 x
Net cash position 2022 13.85M 8.99M Net cash position 2023 3.01M 1.95M EV / Sales 2023 1.59 x
P/E ratio 2022
-3.04 x
P/E ratio 2023
-0.83 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 64.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.08%
1 week-9.46%
Current month-17.28%
1 month-14.10%
3 months-5.63%
6 months+59.52%
Current year-5.63%
More quotes
1 week
0.06
Extreme 0.061
0.07
1 month
0.06
Extreme 0.061
0.11
Current year
0.05
Extreme 0.051
0.11
1 year
0.03
Extreme 0.033
0.17
3 years
0.03
Extreme 0.033
0.81
5 years
0.03
Extreme 0.033
0.99
10 years
0.03
Extreme 0.033
1.80
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 19-02-28
Chief Tech/Sci/R&D Officer - 19-10-15
Members of the board TitleAgeSince
Chairman 69 20-05-07
Director/Board Member 68 16-03-14
Director/Board Member - 20-03-25
More insiders
Date Price Change Volume
24-03-28 0.067 +3.08% 37 671
24-03-27 0.065 +6.56% 28,433
24-03-26 0.061 -6.15% 205,083
24-03-25 0.065 -8.45% 488,610
24-03-22 0.071 -4.05% 327,691

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in the discovery and development of treatments for cancer and inflammation. The Company has three active drug development programs: its clinical drug candidate Veyonda, plus two technology platforms, Chroma (oncology) and Sofra (inflammation and autoimmunity), which provide the basis for the active development of a growing pipeline of drugs. Veyonda (Idronoxil) is an adjuvant therapy in chemotherapy and radiotherapy in the treatment of late-stage cancers. The Chroma drug candidates have bioactive properties, which it is exploring primarily in the anti-cancer space. Its Sofra platform is centered around short nucleic acid sequences called oligonucleotides, which can act on specific cell receptors to stop inflammation, which is a source of various debilitating and lethal diseases. It is also conducting a dose escalation and dose expansion study of NOX66 in the treatment of COVID-19 infection.
More about the company
  1. Stock
  2. Equities
  3. Stock Noxopharm Limited - Australian S.E.